TL;DR:
- PreveCeutical Medical Inc. has established a new division for developing and training an AI tool for optimizing R&D, clinical trials, and other clinical information.
- The company has acquired the domain www.preveceutical.ai and hired Mr. Shawn Sadler as Head of Artificial Intelligence.
- Mr. Sadler has over 25 years of experience in the information technology industry and expertise in Data Management, AI Frameworks, Information Governance, and Machine Learning.
- He will be responsible for developing AI analytics frameworks, preparing data for ingestion into the proprietary Large Language Model (LLM), working with research scientists to improve workflows, analyzing data sets, leveraging predictive analytics, using natural language processing, optimizing data collection and analysis processes, and utilizing data visualization.
- PreveCeutical CEO Stephen Van Deventer believes that AI will play a vital role in the future of medical technology and that the company will be at the forefront of AI technology.
- Van Deventer is thrilled to welcome Mr. Sadler to the PreveCeutical team as the company advances its products through clinical trials and commercialization.
Main AI News:
PreveCeutical Medical Inc. is proud to announce the establishment of a new division dedicated to the creation and training of a state-of-the-art Artificial Intelligence (AI) tool. With the goal of optimizing R&D, clinical trials, and other clinical information, this innovative technology will streamline PreveCeutical’s clinical programs, providing a boost in efficiency, accuracy, and predictive capabilities.
In preparation for the deployment of this AI tool, PreveCeutical has acquired the domain www.preveceutical.ai, which will soon be home to all information regarding the development and implementation of the AI program. To lead this exciting new division, PreveCeutical has hired Mr. Shawn Sadler as Head of Artificial Intelligence, effective April 21, 2023.
With over 25 years of experience in the information technology sector and a wealth of knowledge in Data Management, AI Frameworks, Information Governance, and Machine Learning, Mr. Sadler is poised to bring strategic vision and valuable insights to PreveCeutical. He is an expert in network design and engineering with a proven track record of delivering cutting-edge solutions and exceptional project management skills. Mr. Sadler’s exceptional ability to identify business opportunities and forge strategic partnerships, as well as his expertise in taking projects from ideation to launch, make him the perfect addition to the PreveCeutical team.
As Head of Artificial Intelligence, Mr. Sadler will be tasked with several critical responsibilities, including developing AI analytics frameworks for research data, preparing existing data for ingestion into the proprietary Large Language Model (LLM), working with research scientists to improve workflows through the use of AI tools, analyzing large data sets to uncover unique patterns, leveraging predictive analytics to identify risks, opportunities, and make informed decisions, using natural language processing to extract meaningful insights from text data, optimizing data collection and analysis processes, and utilizing data visualization to make complex data more accessible and understandable for research scientists.
“We believe that artificial intelligence will play a vital role in the future of medical technology,” stated PreveCeutical’s Chief Executive Officer, Stephen Van Deventer. “With Mr. Sadler at the helm of our new AI division, we are confident that PreveCeutical will be at the forefront of AI technology, positioning us as a leader in the pharmaceutical and life sciences industries.“
Van Deventer went on to say, “We are thrilled to welcome Shawn to the PreveCeutical team as we advance our products through clinical trials and commercialization. With his passion for technology and his wealth of experience, he is the ideal candidate to lead this exciting new chapter in our company’s history.”
Conlcusion:
PreveCeutical Medical Inc.’s establishment of a new division dedicated to the development and training of an AI tool, along with the hiring of Mr. Shawn Sadler as Head of Artificial Intelligence, signals a strong commitment to staying at the forefront of AI technology in the medical industry. With Mr. Sadler’s extensive experience and expertise in information technology, PreveCeutical is poised to make significant advancements in optimizing R&D, clinical trials, and other clinical information.
This move is likely to have a positive impact on the market, positioning PreveCeutical as a leader in the pharmaceutical and life sciences industries and potentially leading to new business opportunities and strategic partnerships. Overall, this is a promising development for the market and for PreveCeutical’s future success.
